SCHEMBL25409494

SCHEMBL25409494

Cc1ccc(C=C2CC3(C2)CN(C(=O)OC(C)(C)C)C3)nc1F

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ACACB O00763 6/20 0.41
GRM5 P41594 2/20 0.37
CYP11B2 P19099 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
KRAS P01116 1/20 0.37
PARP1 P09874 3/20 0.36
SCD5 Q86SK9 1/20 0.36
SPR P35270 2/20 0.36
HDAC2 Q92769 2/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26631451 0.84 ACACB (0.38) ACACBGRM5CYP11B2CYP1A2CYP3A4
SCHEMBL26631494 0.83 CYP1A2 (0.34) GRM5CYP1A2CYP3A4
SCHEMBL25411224 0.81 GPR119 (0.39) ACACBCYP11B2KRASSCD5HDAC4
SCHEMBL29497443 0.81 PARP1 (0.37) ACACBGRM5CYP11B2CYP1A2CYP3A4
SCHEMBL26631447 0.81 PARP1 (0.37) ACACBGRM5CYP11B2CYP1A2CYP3A4
SCHEMBL31365772 0.80 GPR119 (0.38) ACACBCYP11B2KRASPARP1SCD5
SCHEMBL25299042 0.80 GPR119 (0.38) ACACBCYP11B2KRASPARP1SCD5
SCHEMBL25325917 0.78 ACACB (0.36) ACACBGRM5CYP11B2CYP1A2CYP3A4
SCHEMBL31308716 0.78 F13A1 (0.41) ACACBSCD5
SCHEMBL30553426 0.78 ACACB (0.36) ACACBGRM5CYP11B2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US disclosed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP disclosed
WO-2022063784-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 WO disclosed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP ACACB 61/4885GRM5 378/4885CYP11B2 649/4885
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP ACACB 60/4885GRM5 368/4885CYP11B2 643/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP ACACB 60/4885GRM5 368/4885CYP11B2 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.